drugset / Trial / NCT00812240

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

NCT00812240

Phase 3 Terminated 335 enrolled AB Science
RandomizedParallel-groupOpen-labelTreatment

Summary

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Timeline

Start
2009-01
Primary completion
2018-07
Completion
2018-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Imatinib Small molecule 400 mg Oral
Comparator Imatinib Small molecule 600 mg Oral
Subject Masitinib Small molecule 6 mg/kg Oral
Subject Masitinib Small molecule 7.5 mg/kg Oral